

PTO/SB/D8A (07-05)

Approved for use through 07/31/2006. OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet	1	of	3
-------	---	----	---

Complete if Known

Application Number	10/562,951
Filing Date	December 23, 2005
First Named Inventor	Brian Anderton, et al.
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	0380-P03923US0

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

[illegible]

Examiner Signature	Date Considered
-----------------------	--------------------

* EXAMINER: Initial file reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Enclose copy of this form with next communication to applicant. * Applicant's unique citation designation number (optional). * The Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. * Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). * For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. * Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. * Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/562,951
Filing Date	December 23, 2005
First Named Inventor	Brian Anderton, et al.
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	0380-P03923US0

Sheet **2** of **3****NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GHOSHAL, N. et al., "A New Molecular Link between the Fibrillar and Granulovacuolar Lesions of Alzheimer's Disease," American Journal of Pathology, 155(4):1163-1172, (1999)	
		HANGER, D. et al., "New Phosphorylation Sites Identified in Hyperphosphorylated Tau (Paired Helical Filament-Tau) from...", Journal of Neurochemistry, 71:2465-2476, (1998)	
		LAMBERT, M. et al., "Diffusible, nonfibrillar ligands derived from AB1-42 are potent central nervous system neurotoxins," Proc. Natl. Acad. Sci., 95:6448-6453, (1998)	
		LEE, V. et al., "Neurodegenerative Tauopathies," Annu. Rev. Neurosci., 24:1121-1159, (2001)	
		MULOT, S. et al., "PHF-tau from Alzheimer's brain comprises four species on SDS-PAGE which can be...", Federation of European Biochemical Societies, 349:359-364, (1994)	
		SHIRAZI, S. et al., "The protein tyrosine kinase, fyn, in Alzheimer's disease pathology," Neuro Report, 4:435-437, (1993)	
		SINGH, T. et al., "Modulation of GSK-3-catalyzed phosphorylation of microtubule-associated protein tau by...", Federation of European Biochemical Societies, 358:4-8, (1995)	
		SINGH, T. et al., "Rapid Alzheimer-like phosphorylation of tau by the synergistic actions...", Federation of European Biochemical Societies, 358:267-272, (1995)	
		WILLIAMSON, R. et al., "Rapid Tyrosine Phosphorylation of Neuronal Proteins Including Tau and Focal Adhesion Kinase in...", The Journal of Neuroscience, 22(1):10-20 (2002)	
		GOEDERT, M. et al., "Cloning and sequencing of the cDNA encoding an isoform of microtubule-associated protein tau containing four...", The EMBO Journal, 8(2):393-399 (1989)	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DJS/

PTO/SB/088 (07-05)

Approved for use through 07/31/2006. OMB 0551-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/562,951
Filing Date	December 23, 2005
First Named Inventor	Brian Anderton, et al.
Art Unit	Not yet assigned
Examiner Name	Not yet assigned
Attorney Docket Number	0380-P03923US0

Sheet 3 of 3

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		GOEDERT, M. et al., "Expression of separate isoforms of human tau protein: correlation with the tau pattern in brain and....," The EMBO Journal, 9(13):4225-4230, (1990)	
		GRAVES, P. et al., "Molecular Cloning, Expression, and Characterization of a 49-Kilodalton Casein....," The Journal of Biological Chemistry, 268(9):6394-6401, (1993)	
		GOEDERT, M. et al., "Multiple Isoforms of Human Microtubule-Associated Protein Tau: Sequences and Localization in Neurofibrillary Tangles of....," Neuron., 3:519-526, (1989)	
		SCALES, T. et al., "Tyrosine Phosphorylation of Specific Sites on Tau by SRC Family Kinases," Neurobiol. Aging, 23:S500-S501, (2002)	

Examiner Signature	/David Steadman/	Date Considered	09/12/2008
-----------------------	------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DJS/